Top 50 Health Care Startup Investors in Australia in December 2024

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.

Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.

Giant Leap is Australia's first venture capital fund to be 100% dedicated to investing in exceptional, rapidly scalable impact businesses.

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Blackbird is a venture capital fund based in Australia and New Zealand. We invest in every type of technology from software to space, unified by the biggest of ambitions.

Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.

AirTree is a venture capital firm investing in Australian and New Zealand technology founders from seed stage or earlier.

Flying Fox Ventures is an early stage investment firm that invests across industry and across the micro-stages of pre-seed and seed.

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Regal Funds Management was founded in 2004 by Andrew and Philip King. Regal utilises a long/short investment strategy and performs investment management and investment advisory services to a number of Australian Unit Trusts and Cayman Island Companies.

Archangel is an early stage venture capital fund based in Australia. We work with great founders and investors to build game changing companies together.

Carthona Capital is a hands-on, proactive, and thematic venture capital investor based in Sydney, Australia that invests globally.

Clinton Capital Partners is a VC advisory business that specialises in raising capital and growing shareholder returns, for early stage technology companies and their investors. In addition, we invest our own funds to align company, investor and advisor. We have completed >70 successful transactions, and crystallised 14 liquidity events.Clinton Capital Partners has a long and established track record of growing companies, raising capital, conducting mergers, and creating liquidity events. When raising capital, we feel early-stage companies underestimate the time involved, the distraction to the underlying business, and the importance of identifying the “right culturally aligned” investors for their journey.

EVP is an early stage venture capital firm based in Sydney Australia with c. $300M FUM across four fund vintages.Our most recent fund was launched in December 2022 and is a $100M fund. The fund targets early Series-A investments initially with cheque sizes in the range of $0.5 – $5.0 million. Our funds invest in software, are sector agnosticand have a focus on Australian based B2B SaaS companies.Over the years, we’ve backed brilliant founders building global software companies like SiteMinder, Deputy, Ignition and Shippit. We make high conviction investments, underpinned by ambition, pragmatism and a deep understanding of the software journey.

OIF is a venture capital firm focusing on partnering with entrepreneurs building businesses.

Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.

Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.

Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.

Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.

Skip Capital is a private investment fund investing in technology and infrastructure

Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.

We are a community-powered VC fund making pre-seed / seed stage investments in Australian and New Zealand startups. Our community is rallied around a shared goal: to invest in the next generation of Australia and New Zealand startups at the very earliest stage, and then support them on their long a

Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.

Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!

Venture capital and technology investments

Bailador is a growth capital fund that focuses on the IT and media sectors, managed by an experienced team with demonstrated sector expertise. The company supports its portfolio companies in subsequent rounds of funding through their own participation and with introductions to larger international growth expansion funds. It assists in thepreparation and management of fundraising, M&A activity, and pre-IPO processes. The portfolio businesses of the company are DocsCorp, Click Loans Group, Rezdy, Stackla, iPRO Solutions, and SiteMinder.Bailador is an Australia-based company that was founded in 2010 by Paul Wilson and David Kirk.

QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.

The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme

Australia's only truly global early stage VC, we believe in and back the most ambitious founders from the earliest stage.

Purpose Ventures is a Venture Capital Fund in Perth Western Australia backing the next generation of entrepreneurs and innovators.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.

The George Institute for Global Health is an independent medical research institute that helps to improve the health of millions of people worldwide. With projects in more than 50 countries, it has raised over 500 million dollars for global health research since 1999, and it has been ranked among the top 10 research institutions in the world forscientific impact by the SCImago Institution Rankings World Report in 2011, 2012, 2013, and 2014.The George Institute for Global Health’s work includes preventing heart disease in India, improving healthcare for Aboriginal and Torres Strait Islander Australians, closing healthcare gaps in China, making roads safer around the world, preventing the complications of diabetes, changing decades old thinking about intensive care, improving outcomes among stroke survivors, using mobile technology to make healthcare accessible worldwide, and developing tools to empower people to improve their own health.The George Institute for Global Health was founded in 1999 and is based in Sydney.

We invest in Western Australian Innovators with bold ideas and global ambitions. We invest at Seed to Series-A in Western Australian companies.

Right Click Capital - Australian Venture Capital Firm

Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.

Everywhere Ventures (fka "The Fund") is a first-of-its-kind early-stage venture fund created ​by founders for founders​ to support the next generation of entrepreneurs.Everywhere Ventures is a community-powered venture investing platform that integrates the capital, expertise, and mentoring of experienced founders and operators acrossten micro funds. The Fund's $50M+ under management comes almost exclusively from the over 500 founders and operators who are its limited partners. Everywhere Ventures operates from the belief that those who have actually built successful companies are best suited to advise and support early-stage startups. Everywhere Ventures invests in pre-seed deals globally usually in the first financing round the company raises. Emphasis is placed on purpose-driven teams across money, health and work verticals.

Venture capital for high growth software companies.

Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.

Adam Schwab, 36, studied Law/Commerce at Monash University before becoming a corporate lawyer specialising in mergers & acquisitions at Freehills (now HerbertSmithFreehills). At 25, Adam co-founded corporate accommodation and services group, Living Corporate Apartments. In 2010, Adam co-founded what would soon become the Lux Group. In2011, Adam co-founded of MyTable, which eventually formed part of Menulog (which was sold to JustEat in 2015). Adam is currently an investor and non-executive director of online art marketplace, BlueThumb.com.au.In 2015, Adam was named the Australian Young Executive of the Year by CEO Magazine, and Adam has been a director of the Myeloma Foundation of Australia since 2010.

Breyer Capital is an independent global venture capital and private equity investor. Founded by Jim Breyer in 2006, we make long-term, idea-driven investments.

Helping passionate founders build the future Saniel Ventures is a private investment group supporting high growth technology companies. Get in touch We invest in people first Smart, passionate, resilient founders building the future We don't expect you to have all the answers, but we do expect that you are humble enough to know

Perennial Partners is a specialist, active investment management firm. Formed in 2000 and led by well-known Value investor, John Murray. The company's sole focus is to deliver excellence in funds management through equity ownership and the alignment of interests between key investment management staff and our clients. Perennial Value nowmanages over $5 billion on behalf of institutional and retail clients.

Gabby Leibovich is the co-founder and managing director at Catch.com.au.

Kurt Alexander

Unilever Ventures is the venture capital and private equity arm of Unilever. We support forward-thinking founders who are crafting brands for the modern consumer.

Serial entrepreneur and investor Founded some of Australia’s most successful B2C companies. Over $500m in exits in the last 5 years.